Reference health

Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials

https://doi.org/10.1136/annrheumdis-2013-203927
CiteStamped reference-health badge
25/25 checkable references clean · checked 2026-07-23

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

4 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 25 checked references that resolve
resolves10.1136/ard.2010.137778
Long-term patient survival in ANCA-associated vasculitis
resolves10.7326/0003-4819-116-6-488
Wegener Granulomatosis: An Analysis of 158 Patients
resolves10.1136/ard.2009.109389
Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis
resolves10.1002/art.33361
Risk factors for relapse of antineutrophil cytoplasmic antibody–associated vasculitis
resolves10.1002/art.24386
Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis
resolves10.1002/acr.20433
A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis
resolves10.3899/jrheum.110276
The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis
resolves10.1002/art.1780400222
Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides
resolves10.1093/qjmed/90.6.391
Damage occurs early in systemic vasculitis and is an index of outcome
resolves10.1093/rheumatology/37.1.57
Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI)
resolves10.3899/jrheum.090387
Predictors of Damage and Survival in Patients with Wegener’s Granulomatosis: Analysis of 50 Patients
resolves10.1093/rheumatology/41.5.572
Predictors of survival and organ damage in Wegener's granulomatosis
resolves10.1002/art.21117
Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)
resolves10.1136/ard.2006.062711
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis
resolves10.1056/NEJMoa041884
Etanercept plus Standard Therapy for Wegener's Granulomatosis
resolves10.1056/NEJMoa020286
A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
resolves10.1681/ASN.2007010090
Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis
resolves10.7326/0003-4819-150-10-200905190-00004
Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated Vasculitis
resolves10.1002/art.21142
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitis
resolves10.1001/jama.2010.1658
Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
resolves10.1056/NEJMoa0909169
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
resolves10.1002/art.1780370206
Nomenclature of Systemic Vasculitides
resolves10.1136/ard.2009.122952
Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index
resolves10.1136/ard.2010.145250
Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials
resolves10.1007/s11926-012-0291-1
Damage Assessment in ANCA-Associated Vasculitis
The 4 references without a DOI — listed, not checked
no DOI — not checkedRevised international Chapel hill consensus conference nomenclature of Vasculitides
no DOI — not checkedOutcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies
no DOI — not checkedEuropean therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL
no DOI — not checkedDevelopment of comprehensive disease assessment in systemic vasculitis
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1136/annrheumdis-2013-203927"><img src="https://citestamp.com/citestamped/10.1136/annrheumdis-2013-203927/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1136/annrheumdis-2013-203927/badge.svg)](https://citestamp.com/citestamped/10.1136/annrheumdis-2013-203927)